Shanghai Labway Clinical Laboratory Valuation
Is 301060 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 301060 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 301060 (CN¥9.98) is trading above our estimate of fair value (CN¥0.26)
Significantly Below Fair Value: 301060 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 301060?
Key metric: As 301060 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 301060's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | CN¥1.72b |
| Market Cap | CN¥4.25b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | -28.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 301060's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
600829 HPGC Renmintongtai Pharmaceutical | 0.4x | n/a | CN¥4.2b |
603122 Cowealth Medical ChinaLtd | 2.9x | n/a | CN¥2.9b |
002462 Cachet Pharmaceutical | 0.1x | n/a | CN¥4.1b |
002788 Luyan PharmaLtd | 0.2x | n/a | CN¥3.4b |
301060 Shanghai Labway Clinical Laboratory | 2.3x | n/a | CN¥4.2b |
Price-To-Sales vs Peers: 301060 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.9x).
Price to Sales Ratio vs Industry
How does 301060's PS Ratio compare vs other companies in the CN Healthcare Industry?
| 8 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
601607 Shanghai Pharmaceuticals Holding | 0.3x | 9.5% | US$10.00b |
600998 Jointown Pharmaceutical Group | 0.2x | 8.0% | US$3.71b |
000028 China National Accord Medicines | 0.2x | 5.7% | US$2.22b |
000950 C.Q. Pharmaceutical Holding | 0.1x | 10.1% | US$1.37b |
| 8 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 301060 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the CN Healthcare industry average (1.8x).
Price to Sales Ratio vs Fair Ratio
What is 301060's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 301060's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥7.1b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥15.53
7D
-5.8%
1Y
-34.9%
Innovita Biological Technology
CN¥6.0b
Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.
688253
CN¥44.03
7D
2.4%
1Y
46.3%
iRay Technology
CN¥16.1b
Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.
688301
CN¥108.85
7D
-3.0%
1Y
-32.1%